




Searching News Database: HUMIRA
HSMN NewsFeed - 14 Feb 2025
AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
HSMN NewsFeed - 21 Feb 2024
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
HSMN NewsFeed - 19 May 2022
Odyssey Therapeutics Appoints Industry Leader Jeffrey M. Leiden, M.D., Ph.D., as Board Chair
Odyssey Therapeutics Appoints Industry Leader Jeffrey M. Leiden, M.D., Ph.D., as Board Chair
HSMN NewsFeed - 2 Feb 2021
Actimed Therapeutics Appoints Frank Misselwitz MD, PhD as Chief Medical Officer
Actimed Therapeutics Appoints Frank Misselwitz MD, PhD as Chief Medical Officer
HSMN NewsFeed - 13 Jan 2021
EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen
EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen
HSMN NewsFeed - 3 Nov 2020
Aethlon Announces Appointment of Charles J. Fisher, Jr., M.D. as Chief Executive Officer
Aethlon Announces Appointment of Charles J. Fisher, Jr., M.D. as Chief Executive Officer
HSMN NewsFeed - 3 Sep 2020
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
HSMN NewsFeed - 10 Aug 2020
NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors
NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors
HSMN NewsFeed - 13 Nov 2019
Abbott Announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020
Abbott Announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020
HSMN NewsFeed - 14 May 2019
Boehringer Ingelheim announces resolution of Cyltezo(R) patent litigation
Boehringer Ingelheim announces resolution of Cyltezo(R) patent litigation
HSMN NewsFeed - 14 May 2019
AbbVie Resolves HUMIRA(R) (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim
AbbVie Resolves HUMIRA(R) (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim
HSMN NewsFeed - 9 Apr 2019
Orgentec Diagnostika Appoints Global Healthcare Leader Gary Winer As President And CEO
Orgentec Diagnostika Appoints Global Healthcare Leader Gary Winer As President And CEO
HSMN NewsFeed - 13 Mar 2019
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
HSMN NewsFeed - 30 Nov 2018
AbbVie Announces HUMIRA(R) (adalimumab) Global Patent License with Pfizer
AbbVie Announces HUMIRA(R) (adalimumab) Global Patent License with Pfizer
HSMN NewsFeed - 18 Oct 2018
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Fresenius Kabi
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Fresenius Kabi
HSMN NewsFeed - 17 Jul 2018
Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations
Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations
HSMN NewsFeed - 5 Apr 2018
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Samsung Bioepis
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Samsung Bioepis
HSMN NewsFeed - 28 Sep 2017
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Amgen
AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Amgen
HSMN NewsFeed - 28 Sep 2017
Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA(TM)
Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA(TM)
HSMN NewsFeed - 21 Jan 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
HSMN NewsFeed - 4 Dec 2015
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
HSMN NewsFeed - 31 Jul 2012
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
HSMN NewsFeed - 8 Nov 2011
Abbott Reports Five-Year Data for HUMIRA(R) (Adalimumab) in Ankylosing Spondylitis
Abbott Reports Five-Year Data for HUMIRA(R) (Adalimumab) in Ankylosing Spondylitis
HSMN NewsFeed - 14 Jun 2011
Micromet Appoints Ulrich Grau, Ph.D. Executive Vice President and Chief Operating Officer
Micromet Appoints Ulrich Grau, Ph.D. Executive Vice President and Chief Operating Officer
HSMN NewsFeed - 10 May 2011
Abbott's HUMIRA(R) (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
Abbott's HUMIRA(R) (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
HSMN NewsFeed - 13 Apr 2011
Raptor Pharmaceutical Adds Three Biopharmaceutical Leaders to Its Board of Directors
Raptor Pharmaceutical Adds Three Biopharmaceutical Leaders to Its Board of Directors
HSMN NewsFeed - 21 Dec 2010
Ramius and Royalty Pharma Extend Tender Offer Until January 5, 2011 Pursuant to Definitive Merger Agreement
Ramius and Royalty Pharma Extend Tender Offer Until January 5, 2011 Pursuant to Definitive Merger Agreement
HSMN NewsFeed - 27 Mar 2009
Nabriva Therapeutics Appoints Dr David Chiswell as Chief Executive Officer
Nabriva Therapeutics Appoints Dr David Chiswell as Chief Executive Officer
HSMN NewsFeed - 27 Feb 2009
Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
HSMN NewsFeed - 4 Sep 2008
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
HSMN NewsFeed - 3 Sep 2008
Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
HSMN NewsFeed - 24 Jun 2008
NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis
NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis
HSMN NewsFeed - 4 Jun 2008
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 22 Feb 2008
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
HSMN NewsFeed - 19 Jan 2008
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
HSMN NewsFeed - 20 Dec 2007
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
HSMN NewsFeed - 16 Nov 2007
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
HSMN NewsFeed - 7 Jun 2007
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
HSMN NewsFeed - 2 Apr 2007
Abbott Seeks U.S. and E.U. Regulatory Approval for HUMIRA(R) (Adalimumab) in Psoriasis
Abbott Seeks U.S. and E.U. Regulatory Approval for HUMIRA(R) (Adalimumab) in Psoriasis
HSMN NewsFeed - 27 Feb 2007
HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment of Crohn's Disease
HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment of Crohn's Disease
HSMN NewsFeed - 24 May 2006
Valera Pharmaceuticals Appoints Jeremy D. Middleton To The Position Of Vice President, Business Development
Valera Pharmaceuticals Appoints Jeremy D. Middleton To The Position Of Vice President, Business Development
Additional items found! 61

Members Archive contains
61 additional stories matching:
HUMIRA
(Password required)
HUMIRA
(Password required)